Merck & Co., Inc.MRK
時価総額
$2518.6億
PER
研究開発型バイオ医薬品・ワクチン・動物用製品の世界最大手。がん免疫療法やワクチン、デジタル獣医保健ソリューションを展開。2024年7月に眼科バイオ企業を約12億ドルで買収。米国・欧州・中国や新興市場を中心に展開。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net income | 982 | 6,392 | 6,299 | 4,517 | 11,934 | 4,459 | 3,941 | 2,418 | 6,193 | 9,777 | 7,082 | - | - | - | 17,133 |
| Amortization | - | - | - | - | - | - | - | - | - | - | 1,899 | 1,636 | 2,085 | 2,044 | 2,395 |
| Depreciation | - | - | - | - | - | - | - | - | - | - | 1,726 | 1,600 | 1,800 | 1,800 | 2,100 |
| Intangible asset impairment charges | - | - | - | - | - | - | - | - | - | - | - | - | - | 792 | 39 |
| (Income) loss from investments in equity securities, net | - | - | - | - | - | - | - | - | - | - | - | 1,940 | -1,419 | 340 | 14 |
| Charges for certain research and development asset acquisitions | - | - | - | - | - | - | - | - | - | - | - | 1,556 | - | - | 3,456 |
| Deferred income taxes | -1,092 | -1,537 | 669 | -330 | -2,600 | -764 | -1,521 | -2,621 | -509 | -556 | -668 | 187 | -1,568 | -1,899 | -1,249 |
| Share-based compensation | 509 | 369 | 335 | 276 | 278 | 299 | 300 | 312 | 348 | 417 | 475 | 479 | 541 | 645 | 761 |
| Other | - | -323 | -28 | -399 | 95 | -757 | -313 | -269 | -978 | -184 | 49 | -805 | -1,301 | -355 | -510 |
| Accounts receivable | 1,089 | 1,168 | -349 | -436 | 554 | 480 | 619 | -297 | 418 | -294 | 1,002 | 2,033 | 644 | 1,148 | 244 |
| Inventories | -1,990 | 678 | 482 | 365 | -79 | -805 | -206 | 145 | 911 | 508 | 855 | 674 | 161 | 816 | 835 |
| Trade accounts payable | 124 | 182 | -302 | 522 | 593 | -37 | 278 | 254 | 230 | 399 | 724 | 405 | -289 | -380 | 182 |
| Accrued and other current liabilities | - | 1,444 | -717 | -397 | 1,635 | -8 | -2,018 | -922 | -341 | 376 | -1,138 | 277 | -50 | 1,783 | -2,328 |
| Income taxes payable | 128 | -277 | -34 | -1,421 | -21 | -266 | 124 | -3,291 | 827 | -2,359 | 560 | -540 | 380 | 214 | 1,023 |
| Noncurrent liabilities | -98 | -7 | -1,747 | -132 | 190 | -277 | -809 | -123 | -266 | -237 | -453 | 484 | -545 | 456 | -49 |
| Other | 160 | 262 | 1,203 | -563 | 98 | 5 | -237 | 1,091 | 674 | 32 | 2,426 | 1,758 | 1,473 | 2,314 | 1,416 |
| Net Cash Provided by Operating Activities | 10,822 | 12,383 | 10,022 | 11,654 | 7,860 | 12,421 | 10,376 | 6,447 | 10,922 | 13,440 | 10,253 | - | - | - | 21,468 |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,863 | 3,372 |
| Purchases of securities and other investments | - | - | - | - | - | - | - | - | - | - | - | - | - | 955 | 519 |
| Proceeds from sale of Seagen Inc. common stock | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,145 | - |
| Proceeds from Sale and Maturity of Other Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,658 | 377 |
| Acquisition of Eyebiotech Limited, net of cash acquired | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,327 | 1,344 |
| Acquisition of Elanco Animal Health Incorporated aqua business | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,303 |
| Acquisition of Harpoon Therapeutics, Inc., net of cash acquired | 256 | 373 | - | 246 | 181 | 146 | 780 | 396 | 431 | 294 | 1,365 | 179 | 121 | - | 746 |
| Acquisition of MK-1045 from Curon Pharmaceutical | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 700 |
| Acquisition of Prometheus Biosciences, Inc., net of cash acquired | - | - | - | - | - | - | - | - | - | 1,040 | 2,696 | 1,554 | - | - | - |
| Acquisition of Imago BioSciences Inc., net of cash acquired | - | - | - | - | 3,700 | 7,598 | - | - | - | 3,620 | 2,545 | 11,174 | - | - | - |
| Other | -150 | 116 | -173 | 57 | 80 | -82 | -453 | -38 | -102 | -378 | -130 | 91 | -32 | 36 | 127 |
| Net Cash Used in Investing Activities | -3,497 | -2,890 | -6,805 | -3,148 | -374 | -4,758 | -3,210 | 2,679 | 4,314 | -2,629 | -9,443 | - | - | - | -7,734 |
| Payments on debt | 1,341 | 1,547 | 22 | 1,775 | 6,617 | 2,906 | 2,386 | 1,103 | 4,287 | - | 1,957 | 2,319 | 2,251 | 1,755 | 1,290 |
| Proceeds from issuance of debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,599 |
| Purchases of treasury stock | 1,593 | 1,921 | 2,591 | 6,516 | 7,703 | 4,186 | 3,434 | 4,014 | 9,091 | 4,780 | 1,281 | 840 | - | 1,346 | 1,306 |
| Dividends paid to stockholders | 4,734 | 4,691 | 5,116 | 5,157 | 5,170 | 5,117 | 5,124 | 5,167 | 5,172 | 5,695 | 6,215 | 6,610 | 7,012 | 7,445 | 7,840 |
| Proceeds from Stock Options Exercised | 363 | 321 | 1,310 | 1,210 | 1,560 | 485 | 939 | 499 | 591 | 361 | 89 | 202 | 384 | 125 | 177 |
| Other | -106 | -22 | 86 | 60 | 208 | 56 | -118 | -195 | -325 | 5 | -436 | -286 | -240 | -328 | -372 |
| Net Cash Used in Financing Activities | -5,441 | -6,904 | -3,267 | -5,990 | -15,113 | -5,270 | -9,044 | -10,006 | -13,160 | -8,861 | -2,832 | - | - | - | -7,032 |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | - | - | - | - | - | - | - | - | -205 | 17 | 253 | -133 | -410 | 23 | -293 |
| Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | - | - | - | - | - | - | - | - | 1,871 | 1,967 | -1,769 | 14 | 4,606 | -5,864 | 6,409 |